Medical Device | May 20, 2022
Olympus announces exclusive U.S. co-marketing agreement with Bracco Diagnostics
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
This new fund is amongst the largest for the sector in India
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugate (AIAC) both with global intellectual property rights
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Subscribe To Our Newsletter & Stay Updated
